ATLANTA, GA – We’re proud to celebrate a major milestone at Springer Wellness & Restorative Health, where Robert Springer, MD, one of our outstanding principal investigators, has successfully completed enrollment for a Phase 3 gout study, and delivered exceptional results that exceeded all expectations.

Dr. Springer and his dedicated site team not only met the study’s enrollment goals, they surpassed the initial enrollment target by over 200%, more than doubling the target enrollment. Even more impressively, the site screened its first patient on the very same day it was activated, demonstrating operational efficiency, readiness, and an unwavering commitment to rapid trial execution.

Equally noteworthy is Dr. Springer’s leadership in diversity enrollment, with 78% of participants identifying as members of underrepresented communities. This achievement underscores the importance of inclusive research practices and highlights the team’s ability to reach and engage with populations that have historically had limited access to clinical trials. Ensuring broader representation helps generate more meaningful data and contributes to the development of treatments that are effective for all.

With 35+ clinical trials conducted in partnership with DelRicht Research, Dr. Springer continues to set the bar for excellence. His proactive, patient-centered approach and deep clinical insight have made him a trusted partner in driving impactful research forward. Whether focused on musculoskeletal health, chronic pain, or general medicine, Dr. Springer exemplifies what it means to lead with purpose and integrity.

We’re grateful for Dr. Springer’s ongoing contributions to advancing care for gout, a condition that causes significant pain and reduced quality of life for millions. His efforts are helping bring promising new therapies to the patients who need them most.

Thank you, Dr. Robert Springer, for your leadership, excellence, and dedication to inclusive, patient-first research.